Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Published:2020-02 Issue:2 Volume:21 Page:271-282
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Doebele Robert C,Drilon Alexander,Paz-Ares Luis,Siena Salvatore,Shaw Alice T,Farago Anna F,Blakely Collin M,Seto Takashi,Cho Byung Chul,Tosi Diego,Besse Benjamin,Chawla Sant P,Bazhenova Lyudmila,Krauss John C,Chae Young Kwang,Barve Minal,Garrido-Laguna Ignacio,Liu Stephen V,Conkling Paul,John Thomas,Fakih Marwan,Sigal Darren,Loong Herbert H,Buchschacher Gary L,Garrido Pilar,Nieva Jorge,Steuer Conor,Overbeck Tobias R,Bowles Daniel W,Fox Elizabeth,Riehl Todd,Chow-Maneval Edna,Simmons Brian,Cui Na,Johnson Ann,Eng Susan,Wilson Timothy R,Demetri George D

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. TRKing down an old oncogene in a new era of targeted therapy;Vaishnavi;Cancer Discov,2015

2. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types;Amatu;ESMO Open,2016

3. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer;Vaishnavi;Nat Med,2013

4. Oncogenes in solid human tumours;Pulciani;Nature,1982

5. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences;Martin-Zanca;Nature,1986

Cited by 1013 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future;ESMO Gastrointestinal Oncology;2024-03

2. Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments;Molecular and Cellular Probes;2024-02

3. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer;Lung Cancer;2024-02

4. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging;Critical Reviews in Oncology/Hematology;2024-02

5. Oncogenic fusions: Targeting NTRK;Critical Reviews in Oncology/Hematology;2024-02